Skip Navigation

U.S. Department of Health & Human ServicesLink to www.hhs.gov
OMH Home

En Español
The Office of Minority Health (Phone: 1-800-444-6472)
About OMH
Our Services
Campaigns/Initiatives
Press Releases
Calendar
Employment
Publications
Federal Clearinghouses
Research
OPHS Home
Image of a person asking a questionNeed Help?
Contact Us


Aids.gov - Access to U.S. Government HIV and AIDS information

To find HIV Test Centers near you Text: Your Zip Code To: KnowIt (566948) www.hivtest.org

HIV/AIDS Awareness Days
Join Our Mailing ListJoin Our Mailing List
Click to sign up


OMH Content via HealthDay

  Last Seven Days' Health News
Savella Approved for Fibromyalgia

Expected in pharmacies by March

THURSDAY, Jan. 15 (HealthDay News) -- Savella (milnacipran hydrochloride) has been approved by the U.S. Food and Drug Administration to treat fibromyalgia, a chronic condition characterized by restricted movement and widespread pain, makers Forest Labs and Cypress Bioscience announced.

The safety and effectiveness of the drug, a selective serotonin and norepinephrine dual reuptake inhibitor, were established in clinical trials involving 2,084 patients. In a news release, the drug's makers said it's not known exactly how Savella improves symptoms of fibromyalgia, which some scientists believe is related to abnormalities in certain brain neurotransmitters.

As many as 6 million Americans have fibromyalgia, making it the second-most common condition diagnosed in rheumatology clinics behind osteoarthritis, the companies said. There is no cure.

Savella is expected in pharmacies by March. Common side effects reported during clinical testing included constipation, hot flushes, vomiting, heart palpitations, dry mouth, and a rise in blood pressure.

More information

The FDA has more information about this drug.

Attribution: -- Scott Roberts
Copyright © 2009 ScoutNews, LLC Exit Disclaimer. All rights reserved.

HealthDayNews articles are derived from various sources and do not reflect federal policy.
omhrc.gov does not endorse opinions, products, or services that may appear in news stories.
Content Last Modified: 1/15/2009 4:31:00 PM
OMH Home  |  HHS Home  |  USA.gov  |  Disclaimer  |  Privacy Policy  |  HHS FOIA  |  Accessibility  |  Site Map  |  Contact Us  |  File Formats

Office of Minority Health
Toll Free: 1-800-444-6472 / Fax: 301-251-2160
Email: info@omhrc.gov

Provide Feedback